Cargando…

Immunomodulatory Properties of DNA Hypomethylating Agents: Selecting the Optimal Epigenetic Partner for Cancer Immunotherapy

DNA hypomethylating agents (DHAs) play a well-acknowledged role in potentiating the immunogenicity and the immune recognition of neoplastic cells. This immunomodulatory activity of DHAs is linked to their ability to induce or to up-regulate on neoplastic cells the expression of a variety of immune m...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fazio, Carolina, Covre, Alessia, Cutaia, Ornella, Lofiego, Maria Fortunata, Tunici, Patrizia, Chiarucci, Carla, Cannito, Sara, Giacobini, Gianluca, Lowder, James N., Ferraldeschi, Roberta, Taverna, Pietro, Di Giacomo, Anna Maria, Coral, Sandra, Maio, Michele
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2018
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6293200/ https://www.ncbi.nlm.nih.gov/pubmed/30581389 http://dx.doi.org/10.3389/fphar.2018.01443

Ejemplares similares

Circulating Levels of PD-L1 in Mesothelioma Patients from the NIBIT-MESO-1 Study: Correlation with Survival
por: Chiarucci, Carla, et al.
Publicado: (2020)

Epigenetic Immune Remodeling of Mesothelioma Cells: A New Strategy to Improve the Efficacy of Immunotherapy
por: Lofiego, Maria Fortunata, et al.
Publicado: (2021)

Immunotherapy of brain metastases: breaking a “dogma”
por: Di Giacomo, Anna Maria, et al.
Publicado: (2019)

Immunomodulatory activity of SGI-110: a basis for novel chemo-immunotherapeutic combinations in cancer treatment
por: Covre, Alessia, et al.
Publicado: (2013)

Tremelimumab plus durvalumab retreatment and 4-year outcomes in patients with mesothelioma: a follow-up of the open label, non-randomised, phase 2 NIBIT-MESO-1 study
por: Calabrò, Luana, et al.
Publicado: (2021)

Severe acute respiratory syndrome coronavirus 2 vaccination and cancer therapy: A successful but mindful mix
por: Di Giacomo, Anna M., et al.
Publicado: (2021)

Immune correlates of metastatic melanoma patients treated with ipilimumab in combination with fotemustine in the phase II NIBIT-M1 study
por: Maccalli, Cristina, et al.
Publicado: (2013)

Landscape of immune-related signatures induced by targeting of different epigenetic regulators in melanoma: implications for immunotherapy
por: Anichini, Andrea, et al.
Publicado: (2022)

Guadecitabine plus ipilimumab in unresectable melanoma: five-year follow-up and integrated multi-omic analysis in the phase 1b NIBIT-M4 trial
por: Noviello, Teresa Maria Rosaria, et al.
Publicado: (2023)

SARS-CoV-2 infection in cancer patients on active therapy after the booster dose of mRNA vaccines
por: Di Giacomo, Anna M., et al.
Publicado: (2022)

Efficacy and epigenetic interactions of novel DNA hypomethylating agent guadecitabine (SGI-110) in preclinical models of hepatocellular carcinoma
por: Jueliger, Simone, et al.
Publicado: (2016)

A vision of immuno-oncology: the Siena think tank of the Italian network for tumor biotherapy (NIBIT) foundation
por: Maio, Michele, et al.
Publicado: (2021)

Methylation levels of the "long interspersed nucleotide element-1" repetitive sequences predict survival of melanoma patients
por: Sigalotti, Luca, et al.
Publicado: (2011)

Epigenetics of human cutaneous melanoma: setting the stage for new therapeutic strategies
por: Sigalotti, Luca, et al.
Publicado: (2010)

Whole genome methylation profiles as independent markers of survival in stage IIIC melanoma patients
por: Sigalotti, Luca, et al.
Publicado: (2012)

Gestational stage affects amniotic epithelial cells phenotype, methylation status, immunomodulatory and stemness properties
por: Barboni, Barbara, et al.
Publicado: (2014)

COVID and Lung Cancer
por: Calabrò, Luana, et al.
Publicado: (2021)

B Lymphocytes as Targets of the Immunomodulatory Properties of Human Amniotic Mesenchymal Stromal Cells
por: Magatti, Marta, et al.
Publicado: (2020)

Amniotic mesenchymal cells from pre‐eclamptic placentae maintain immunomodulatory features as healthy controls
por: Pianta, Stefano, et al.
Publicado: (2015)

Intimate partner abuse before and during pregnancy as risk factors for postpartum mental health problems
por: Desmarais, Sarah L, et al.
Publicado: (2014)

The Immunomodulatory Properties of Amniotic Cells: The Two Sides of the Coin
por: Magatti, Marta, et al.
Publicado: (2018)

A novel microRNA signature for the detection of melanoma by liquid biopsy
por: Sabato, Claudia, et al.
Publicado: (2022)

IRX1 hypomethylation in osteosarcoma metastasis
por: Lu, Jinchang, et al.
Publicado: (2015)

Consistent DNA Hypomethylations in Prostate Cancer
por: Araúzo-Bravo, Marcos J., et al.
Publicado: (2022)

Challenges in lung cancer therapy during the COVID-19 pandemic
por: Calabrò, Luana, et al.
Publicado: (2020)

Comparison of Hypomethylator Monotherapy with Hypomethylator plus Chemotherapy for Intermediate/High-Risk MDS or AML: A Meta-Analysis
por: Ji, Jiang, et al.
Publicado: (2020)

Treatment of Low-Blast Count AML using Hypomethylating Agents
por: De Bellis, Eleonora, et al.
Publicado: (2017)

Perinatal derivatives: How to best validate their immunomodulatory functions
por: Papait, Andrea, et al.
Publicado: (2022)

Hypomethylation-induced regulatory programs in T cells unveiled by transcriptomic analyses
por: Lysandrou, Memnon, et al.
Publicado: (2023)

Epigenetic remodelling of gene expression profiles of neoplastic and normal tissues: immunotherapeutic implications
por: Coral, S, et al.
Publicado: (2012)

LINE-1 hypomethylation in familial and sporadic cancer
por: Pavicic, Walter, et al.
Publicado: (2012)

Naïve pluripotency is associated with global DNA hypomethylation
por: Leitch, Harry G., et al.
Publicado: (2013)

LINE-1 and Alu hypomethylation in mucoepidermoid carcinoma
por: Sirivanichsuntorn, Porntipa, et al.
Publicado: (2013)

Analyses of Hypomethylated Oil Palm Gene Space
por: Low, Eng-Ti L., et al.
Publicado: (2014)

Clinical Results of Hypomethylating Agents in AML Treatment
por: Cruijsen, Marjan, et al.
Publicado: (2014)

Hypomethylation Causes MIR21 Overexpression in Tumors
por: Lu, Jun, et al.
Publicado: (2020)

The association between Alu hypomethylation and the severity of hypertension
por: Thongsroy, Jirapan, et al.
Publicado: (2022)

The genome-wide mutational consequences of DNA hypomethylation
por: Besselink, Nicolle, et al.
Publicado: (2023)

Risk of infection in elderly patients with AML and MDS treated with hypomethylating agents
por: Livio, Pagano, et al.
Publicado: (2018)

Immunomodulatory action of the DNA methyltransferase inhibitor SGI-110 in epithelial ovarian cancer cells and xenografts
por: Srivastava, Pragya, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_4s3utuolhod5hat91flv39u2ke